Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV)

Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV)

We previously reported the first-in-human assessment of three doses (2, 5, and 10 µg) of purified inactivated Zika virus vaccine (PIZV or TAK-426) in the Phase 1 ZIK-101 study (NCT03343626). Here, we report dose selection based on extended safety and immunogenicity data (6 months post-vaccination) a...

Full description

Bibliographic Details
Main Authors: Camilo J. Acosta, Francesco Nordio, Eloi Kpamegan, Kelley J. Moss, Pradeep Kumar, Kazuhiro Hirata
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Microorganisms
Subjects:
PIZV
TAK-426
Zika virus
purified inactivated Zika vaccine
dose selection
safety
Online Access:https://www.mdpi.com/2076-2607/12/7/1492

Internet

https://www.mdpi.com/2076-2607/12/7/1492

Similar Items